Clinical Trials Logo
  1. Home
  2. Breakthrough Pain
  3. NCT00236145

Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

Breakthrough Pain Clinical Trial

Official title:
A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain

Clinical Trial Summary

The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a successful dose of ACTIQ treatment more quickly. The successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after a single administration, as assessed by the patient.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00236145
Study type Interventional
Source Teva Pharmaceutical Industries
Contact
Status Completed
Phase Phase 3
Start date June 2004
View Details
See also
  Status Clinical Trial Phase
Completed NCT00994760 - Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years N/A
Completed NCT01842893 - Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer Phase 3
Completed NCT02886286 - Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain Phase 4
Completed NCT02869321 - Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Phase 4
Completed NCT02840500 - Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units N/A
Completed NCT02437929 - Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment N/A
Completed NCT02836379 - Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent N/A
Active, not recruiting NCT02278601 - Comparison of Regimens MPIB, CIPCEA, PCEA Phase 3
Terminated NCT00842829 - Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients Phase 4
Recruiting NCT05200806 - A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy Phase 4
Withdrawn NCT03809455 - Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients Phase 2
Completed NCT03435120 - Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
Completed NCT02050503 - Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis N/A
Terminated NCT00387010 - Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain Phase 3
Withdrawn NCT05053308 - Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement N/A
Recruiting NCT04011150 - Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour Phase 3
Terminated NCT01901718 - An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray. N/A
Completed NCT00402350 - Staccato Fentanyl Single and Multidose PK Phase 1
Completed NCT00236041 - Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP) Phase 2